Methicillin-resistant Staphylococcus Aureus Drugs Market Size & Share 2024 - 2032

Methicillin-resistant Staphylococcus Aureus Drugs Market Size

Methicillin-Resistant Staphylococcus Aureus Drugs Market size was valued at USD 4.1 billion in 2023 and is anticipated to grow at a CAGR of 4.2% between 2024 – 2032. One of the primary drivers is the increasing prevalence of MRSA infections globally, particularly in healthcare settings.

Additionally, rising cases of antibiotic resistance, further drives the market growth. For instance, as per the CDC's 2019 Antibiotic Resistance (AR) Threats Report, more than 2.8 million antimicrobial-resistant infections occur each year, resulting in more than 35,000 deaths in the U.S. Moreover, rising awareness about the seriousness of MRSA infections among healthcare providers and patients is driving the demand for effective treatment options. Furthermore, the growing research and development activities in the field of antimicrobial agents, along with the development of novel therapies targeting MRSA, are expected to contribute to market growth.
 

Methicillin-resistant staphylococcus aureus (MRSA) drugs are medications specifically designed to treat infections caused by Staphylococcus aureus bacteria that have developed resistance to methicillin and other commonly used antibiotics. MRSA infections can range from mild skin infections to more severe and potentially life-threatening infections such as pneumonia and bloodstream infections.
 

Methicillin-resistant Staphylococcus Aureus Drugs Market Trends

• Increasing incidence of methicillin-resistant staphylococcus aureus (MRSA) infections is a significant growth driver for the market. For instance, according to the Centers for Disease Control and Prevention, there are more than 80,000 cases of MRSA each year, and more than 11,000 people die from these infections. Similarly, as per a study published by National Institute of Health (NIH), the pooled global prevalence of MRSA was 14.69%
   
• Thus, as the incidence of MRSA infections continues to rise globally, there is a growing need for effective treatment options, driving the demand for MRSA drugs.
   
• Pharmaceutical companies are investing in research and development to develop new antibiotics and therapies to combat MRSA, contributing to the growth of the MRSA drugs market.
   
• Additionally, the increasing awareness about MRSA and its potential complications among healthcare professionals and the public is also driving market growth, as early detection and treatment are crucial in managing MRSA infections.
   

Methicillin-resistant Staphylococcus Aureus (MSRA) Drugs Market Analysis

Based on drug type, the market is segmented into glycopeptides, lipopeptides, oxazolidinones, cephalosporin, tetracycline, folate antagonist, and other drug classes. The glycopeptides segment dominated the market is 2023 and accounted for USD 1.2 billion.
 

• High market share is attributed to their broad-spectrum activity against gram-positive bacteria, including MRSA, and their established efficacy in treating severe MRSA infections.
   
• Glycopeptide antibiotics, such as vancomycin and teicoplanin are highly effective against MRSA infections. Their ability to disrupt bacterial cell wall synthesis contributes to their efficacy.
   
• Additionally, their long history of successful clinical use and relatively favorable safety profile further bolster their market position, making them a cornerstone in the treatment of MRSA infections worldwide.

Learn more about the key segments shaping this market

Download Free PDF

Based on MRSA type, the methicillin-resistant staphylococcus aureus drugs market is segmented into hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). The hospital-acquired (HA-MRSA) segment dominated the market with 56% of market share in 2023.
 

• Hospitals often host many patients with compromised immune systems, making them more susceptible to infections. For instance, about 10% of hospital-associated infections in the U.S. are caused by MRSA, and these infections are linked to a higher risk of mortality.
   
• Additionally, the frequent use of invasive medical devices such as catheters and ventilators provide MRSA with opportunities to enter the body.
   
• Further, the proximity of patients in hospitals, coupled with the high frequency of healthcare worker-patient interactions, increases the likelihood of MRSA transmission.
   
• Lastly, inadequate infection control practices, including suboptimal hand hygiene compliance, contribute significantly to the spread of HA-MRSA within healthcare facilities, thereby contributing to the high market share of HA-MRSA infections.
   

Based on route of administration, the methicillin-resistant staphylococcus aureus drugs market is categorized into oral and parenteral. The parenteral segment dominated the market in 2023 and is predicted to grow at CAGR of 3.8% over the forecast period.
 

• Parenteral administration offers a direct and rapid delivery of drugs into the bloodstream, ensuring a quick onset of action and high bioavailability. This is crucial in treating severe MRSA infections, where immediate and effective therapy is essential.
   
• Additionally, parenteral formulations are often preferred in hospital settings for patients who are unable to take oral medications or require intensive care.
   
• Further, the convenience of parenteral administration, coupled with the effectiveness of MRSA drugs delivered through this route, has led to the high market share of the parenteral segment in the MRSA drugs market.
   

Based on indication, the methicillin-resistant staphylococcus aureus drugs market is categorized into skin and soft tissue infections, bone & joint infections, respiratory infections, bacteraemia, and other indications. The skin and soft tissue infections segment dominated the market in 2023 and is anticipated to reach USD 2.1 billion by 2032.
 

• The prevalence of MRSA-related skin and soft tissue infections has been increasing due to factors such as antibiotic overuse, inadequate infection control measures, and the spread of resistant strains. Skin and soft tissue infections like cellulitis, abscesses, and wound infections, are among the most common types of infections caused by MRSA.
   
• This rising incidence has created a substantial patient population in need of effective treatment options, thus driving demand for drugs targeting this segment.
   
• Additionally, pharmaceutical companies are investing in research and development efforts to bring to market novel MRSA drugs with enhanced efficacy and safety profiles for treating skin infections, further consolidating the segment's market dominance.
   

Based on distribution channel, the methicillin-resistant staphylococcus aureus drugs market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is anticipated to witness growth at a CAGR of 4.1% between 2024 – 2032.
 

• Hospital pharmacies are often the primary dispensers of medications for MRSA infections, given the high prevalence of these infections in healthcare settings.
   
• Additionally, hospitals are key locations for treating severe cases of MRSA infections, which often require intravenous antibiotics and other specialized medications that are stocked and administered by hospital pharmacies.
   
• Further, the close collaboration between healthcare providers and hospital pharmacists ensures the appropriate use and monitoring of MRSA drugs, further cementing the role of hospital pharmacies in the market.

North America methicillin-resistant staphylococcus aureus drugs market is anticipated to grow at a CAGR of 3.9% over the forecast years to reach USD 2.6 billion by 2032.
 

• The region's strong market position is attributed to advanced healthcare infrastructure, high awareness levels about infectious diseases, and robust research and development activities.
   
• Additionally, the presence of key market players and the adoption of advanced treatment options contribute to North America's dominance in the MRSA drugs market.
   
• Moreover, the region's stringent regulatory framework and favorable reimbursement policies further support market growth.
   

U.S. MSRA drugs market was valued at USD 1.7 billion in 2023.
 

• High market growth can be attributed to the high prevalence of MRSA infections in the country, driving the demand for effective treatment options.
   
• Additionally, the U.S. has a robust healthcare infrastructure and a strong emphasis on research and development, leading to the availability of advanced MRSA drugs.
   
• Moreover, the presence of major pharmaceutical companies and a favorable reimbursement landscape further contributes to the market's growth.
   

UK has emerged as a key player in the global market for methicillin-resistant staphylococcus aureus drugs, showcasing high growth potential.
 

• The country's strong healthcare infrastructure and high healthcare expenditure support the demand for advanced MRSA treatments.
   
• Additionally, the rising prevalence of MRSA infections, particularly in healthcare settings, drives the need for effective medications.
   
• Moreover, increasing awareness about antibiotic resistance further propels the market growth by encouraging the development and adoption of novel therapies.
   

China methicillin-resistant staphylococcus aureus drugs market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country's large population, rapid urbanization, and increasing healthcare expenditure contribute to a high demand of MRSA drugs. This, coupled with a growing awareness about healthcare-associated infections, further drives the demand for effective MRSA drugs.
   
• Additionally, government's initiatives to improve healthcare infrastructure and access to essential medicines further support market growth.
   
• Moreover, the presence of a large number of pharmaceutical companies and research institutions focusing on antimicrobial drug development, further enhance the market growth in the country.
   

Methicillin-resistant Staphylococcus Aureus Drugs Market Share

The methicillin-resistant staphylococcus aureus drugs industry is characterized by the presence of leading pharmaceutical companies. The key market players include Johnson & Johnson, AbbVie Inc., Merck & Co., Inc., and Novartis AG which are focused on developing improved treatments, such as longer-acting formulations and innovative therapies. Market players compete on factors like efficacy, safety, patient convenience, and cost-effectiveness.
 

Methicillin-resistant Staphylococcus Aureus Drugs Market Companies

Prominent players operating in the methicillin-resistant staphylococcus aureus drugs industry include:

• AbbVie Inc.
• Basilea Pharmaceutica Ltd
• Baxter International Inc.
• Cumberland Pharmaceuticals Inc.
• GlaxoSmithKline plc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
   

Methicillin-resistant Staphylococcus Aureus Drugs Industry News:

• In April 2024, Basilea Pharmaceutica Ltd announced that the U.S. FDA approved ZEVTERA (ceftobiprole medocaril sodium for injection) for treating adult patients with Staphylococcus aureus bloodstream infections (bacteremia). The FDA approval allowed the company to bring ZEVTERA to patients in the U.S., expanding its commercial presence and revenue potential.
   
• In July 2021, Melinta Therapeutics launched KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). This helped the company expand its product portfolio.
   

The methicillin-resistant staphylococcus aureus drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Glycopeptides
• Lipopeptides
• Oxazolidinones
• Cephalosporin
• Tetracycline
• Folate antagonist
• Other drug classes

Market, By MRSA Type

• Hospital-acquired (HA-MRSA)
• Community-acquired (CA-MRSA)

Market, By Route of Administration

• Oral
• Parenteral

Market, By Indication

• Skin and soft tissue infections
• Bone & joint infections
• Respiratory infections
• Bacteremia
• Other indications

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa